glimepiride has been researched along with liraglutide in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (11.63) | 29.6817 |
| 2010's | 27 (62.79) | 24.3611 |
| 2020's | 11 (25.58) | 2.80 |
| Authors | Studies |
|---|---|
| Bode, B; Garber, A; Garcia-Hernandez, PA; Hale, PM; Henry, R; Olvera-Alvarez, I; Ratner, R; Rodriguez-Pattzi, H; Zdravkovic, M | 1 |
| Düring, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, IH; Nauck, M; Shah, NS; Tankova, T; Zdravkovic, M | 1 |
| Alfonso-Cristancho, R; Blonde, L; Conner, C; Hammer, M; Sullivan, SD | 2 |
| Düring, M; Frid, A; Garber, AJ; Hermansen, K; Jendle, J; Matthews, DR; Nauck, MA; Strauss, BJ; Zdravkovic, M | 1 |
| Hammer, M; Hermansen, K; Kolotkin, RL; Matthews, D; Zdravkovic, M | 1 |
| Blonde, L; Bode, BW; Garber, A; Hale, PM; Hammer, M; Magwire, M; Testa, MA | 1 |
| Bech, OM; Bhattacharyya, A; Chen, L; Ji, Q; Kim, KW; Kumar, A; Liu, X; Ma, J; Tandon, N; Yang, W; Yoon, KH; Zychma, M | 1 |
| Conner, C; Hammer, M; Lee, WC | 2 |
| Bode, B; Chang, CT; Garber, A; Hale, P; Henry, RR; Ratner, R | 1 |
| Freeman, JS | 1 |
| Mori, Y; Sezaki, K; Taniguchi, Y; Utsunomiya, K; Yokoyama, J | 1 |
| Jermendy, G | 1 |
| Nauck, MA | 1 |
| Chapman, IM; Doran, S; Flint, A; Hindsberger, C; Horowitz, M; Jax, T; Jones, KL; Kapitza, C; Rasmussen, MF; Zdravkovic, M | 1 |
| Bøgelund, M; Ericsson, Å; Jendle, J; Nilsen, B; Ridderstråle, M; Torffvit, O | 1 |
| During, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, I; Nauck, M; Shah, N; Tankova, T; Thomsen, AB | 1 |
| Gao, L; Li, SC; Zhao, FL | 1 |
| Mateos, JL; Wajchenberg, BL | 1 |
| He, H; Lin, H; Liu, D; Ni, Y; Wang, B; Yan, Z; Zhao, Z; Zhong, J; Zhu, Z | 1 |
| Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L | 1 |
| Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D | 1 |
| Bagger, JI; Faber, J; Hansen, T; Holst, JJ; Knop, FK; Pedersen, O; Vilsbøll, T; Østoft, SH | 1 |
| Persson, U; Steen Carlsson, K | 1 |
| Jensen, TM; Saha, K; Steinberg, WM | 1 |
| Brunetti, A; Capula, C; Chiefari, E; Foti, D; Greco, M; Liguori, R; Oliverio, R; Puccio, L; Pullano, V; Tirinato, D; Vero, A; Vero, R | 1 |
| Baeres, FM; Garber, A; Gilbert, MP; Holst, JJ; Marre, M; Pratley, RE; Thomsen, H | 1 |
| Kadonosono, K; Morita, S; Nagakura, J; Shigematsu, E; Suzuki, J; Taguri, M; Terauchi, Y; Tsuchiya, H; Yamakawa, T | 1 |
| Bien, Z; Heald, AH; Laing, I; Livingston, M; Moreno, GYC; Stedman, M | 1 |
| Digtiar, NI; Kaidashev, IP; Kaidasheva, EI; Savchenko, LG; Selikhova, LG; Shlykova, OA; Vesnina, LE | 1 |
| Hyötyläinen, T; Jendle, J; Nyström, T; Orešič, M | 1 |
| Balasubramanyam, A; Burch, HB; Buse, JB; Butera, NM; Cohen, RM; Crandall, JP; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Rasouli, N; Tiktin, M; Wexler, DJ; Younes, N | 1 |
| Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N | 1 |
| Crown, W; Deng, Y; Dhruva, SS; Gandotra, C; Herrin, J; Lyon, TD; McCoy, RG; Noseworthy, P; Polley, EC; Quinto, K; Ross, JS; Shah, ND; Wallach, JD; Yao, X | 1 |
| Cauchon, M; Lanthier, L; Mutchmore, A; Plourde, MÉ | 1 |
| Brown, K; Donato, AA | 2 |
| Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N | 1 |
| Jendle, J; Kruse, R; Nyström, T; Scherbak, NN | 2 |
| Lee, DY | 1 |
8 review(s) available for glimepiride and liraglutide
| Article | Year |
|---|---|
Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Liraglutide; Peptides; Sulfonylurea Compounds; Thyroid Neoplasms; Venoms | 2010 |
Optimizing outcomes for GLP-1 agonists.
Topics: Algorithms; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Weight Loss | 2013 |
[Liraglutide: new results in the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2012 |
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Topics: Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypertension; Hypoglycemic Agents; Insulin; Liraglutide; Male; Peptides; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2013 |
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Pancreatitis; Pancreatitis, Chronic; Randomized Controlled Trials as Topic; Risk Factors; Sulfonylurea Compounds | 2015 |
22 trial(s) available for glimepiride and liraglutide
| Article | Year |
|---|---|
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Sulfonylurea Compounds | 2009 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Obesity; Placebos; Safety; Sulfonylurea Compounds | 2009 |
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Humans; Liraglutide; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2009 |
A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Blood Pressure; Cohort Studies; Computer Simulation; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Models, Theoretical; Morbidity; Sulfonylurea Compounds; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Weight Loss; Young Adult | 2009 |
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Patient Satisfaction; Quality of Life; Sulfonylurea Compounds; Treatment Outcome | 2010 |
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Weight Gain | 2010 |
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Blood Pressure; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; India; Liraglutide; Male; Metformin; Middle Aged; Republic of Korea; Sulfonylurea Compounds; Weight Loss; Young Adult | 2011 |
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2011 |
Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
Topics: Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Quality of Life; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United States | 2011 |
Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study.
Topics: Adult; Aged; Asian People; Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Pilot Projects; Sulfonylurea Compounds; Young Adult | 2011 |
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Appetite; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Energy Intake; Energy Metabolism; Female; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Obesity; Sulfonylurea Compounds; Young Adult | 2012 |
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult | 2013 |
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Postprandial Period; Receptors, Glucagon; Sulfonylurea Compounds; Young Adult | 2014 |
COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.
Topics: Adult; Aged; Bone Density; Calcium; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2016 |
Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Exenatide; Female; Glucose; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Japan; Liraglutide; Male; Middle Aged; Monitoring, Ambulatory; Peptides; Subcutaneous Tissue; Sulfonylurea Compounds; Venoms | 2016 |
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Topics: Aged; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Lipidomics; Lipids; Liraglutide; Male; Metabolome; Metabolomics; Metformin; Middle Aged; Spectrometry, Mass, Electrospray Ionization; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2021 |
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
Topics: Blood Glucose; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Microvessels; Sitagliptin Phosphate; Sulfonylurea Compounds | 2022 |
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Rate; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Kidney; Kidney Diseases; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate | 2023 |
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Liraglutide; MicroRNAs | 2023 |
13 other study(ies) available for glimepiride and liraglutide
| Article | Year |
|---|---|
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Models, Econometric; Peptides; Quality-Adjusted Life Years; Statistics, Nonparametric; Sulfonylurea Compounds; United States; Venoms | 2010 |
Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
Topics: Cost of Illness; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Disease Management; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2012 |
Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Topics: China; Confidence Intervals; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Health Care Costs; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Metformin; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2012 |
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles | 2014 |
Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy.
Topics: Aged; Blood Glucose; Blood Glucose Self-Monitoring; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Retrospective Studies; Sex Factors; Sulfonylurea Compounds; Treatment Outcome; Waist Circumference | 2015 |
The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Prescriptions; England; Exenatide; General Practice; Gliclazide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Practice Patterns, Physicians'; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Venoms | 2018 |
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
Topics: Actins; Ceruloplasmin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gene Expression; Humans; Hypoglycemic Agents; I-kappa B Proteins; Inflammation; Interleukin-2; Leukocytes, Mononuclear; Liraglutide; Male; Metformin; Middle Aged; NF-kappa B; Nod1 Signaling Adaptor Protein; Obesity; Pilot Projects; Prospective Studies; RNA, Messenger; Signal Transduction; Sirtuin 1; Sulfonylurea Compounds; Toll-Like Receptor 2; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2019 |
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2022 |
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
Topics: Diabetes Mellitus, Type 2; Humans; Liraglutide; MicroRNAs; Sulfonylurea Compounds | 2023 |
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
Topics: Diabetes Mellitus, Type 2; Humans; Liraglutide; MicroRNAs; Sulfonylurea Compounds | 2023 |